PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human ...

“High accuracy, long-read sequencing is essential to Intus Bio’s ability to unlock the microbiome, making GutID not just a test, but a transformative tool for understanding and improving human ...

Pacific Biosciences of California, Inc. PACB and Intus Bio, a leader in microbiome research and discovery, recently unveiled ...

Over the past decade, the development of new sequencing technologies has enabled extensive characterization of microorganisms living in or on the human body (the "human microbiome"). In particular, ...

A primary driver is the growing interest in the human microbiome. The global microbiome sequencing services market is projected to reach $5.5b by 2030 at a compound annual growth rate of 18.1% ...

A study involving Black and Hispanic women identified two BV subtypes, with one significantly raising chlamydia risk.

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud ...